Kuros Biosciences Ltd.
Develops biologic technologies for tissue repair and bone regeneration.
KURN | SW
Overview
Corporate Details
- ISIN(s):
- CH0325814116
- LEI:
- 5299006U5POB2AVTT709
- Country:
- Switzerland
- Address:
- Wagisstraße 25, 8952 Schlieren
- Website:
- https://kurosbio.com/
- Sector:
- Manufacturing
Description
Kuros Biosciences is a life sciences company that discovers, develops, and delivers innovative biologic technologies focused on tissue repair and bone regeneration. The company's mission is to address unmet clinical needs for safer, faster, and more predictable bone healing. Its primary commercial product is MagnetOs, an advanced bone graft designed to enhance bone formation. The efficacy of MagnetOs is supported by a comprehensive global research program, "Project Fusion," which includes scientific, pre-clinical, and Level I human clinical studies. Kuros Biosciences serves surgeons and patients across multiple medical fields, including spine, extremities, trauma, and oncology, leveraging deep scientific expertise and collaboration with leading clinical experts.
Unlock This Filing & Millions More
You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.
Filings
| Date | Filing | Language | Size | Actions | |
|---|---|---|---|---|---|
| 2010-02-03 07:00 |
Cytos Biotechnology announces full year 2009 financial results and major develo…
|
English | 2.1 KB | ||
| 2009-11-10 18:00 |
Cytos Biotechnology updates on the development of the hypertension vaccine CYT0…
|
English | 11.9 KB | ||
| 2009-10-22 07:00 |
Cytos Biotechnology AG Third Quarter Report 2009
|
English | 3.0 KB | ||
| 2009-10-15 17:55 |
Interim analysis of an ongoing phase II study with nicotine vaccine shows prima…
|
English | 7.7 KB | ||
| 2009-07-31 07:00 |
Cytos Biotechnology AG: CYT003-QbG10 monotherapy for the treatment of allergic …
|
English | 12.7 KB | ||
| 2009-07-23 07:00 |
Cytos Biotechnology Ltd Second Quarter Report 2009
|
English | 2.9 KB | ||
| 2009-06-24 18:00 |
Cytos Biotechnology reports biochemical findings from phase IIa study with hype…
|
English | 11.1 KB | ||
| 2009-06-11 07:00 |
Cytos Biotechnology Ltd: Initiation of combined phase I/IIa study with a novel …
|
English | 9.5 KB | ||
| 2009-04-22 17:35 |
Cytos Biotechnology AG: First Quarter Report 2009
|
English | 4.1 KB | ||
| 2009-04-21 17:35 |
Cytos Biotechnology Ltd: Start of phase IIa study with CYT003-QbG10 monotherapy…
|
English | 7.0 KB |
Automate Your Workflow. Get a real-time feed of all Kuros Biosciences Ltd. filings delivered via API.
Market Data
Market Data Not Available
Financials & KPIs
Unlock Full Financials for Kuros Biosciences Ltd.
This data is available as part of our premium data solutions. Contact our team for access.
Need More History? Access decades of standardized financials for Kuros Biosciences Ltd. via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| 2025-04-23 | N/A | Executive member | Sell | None | 1,264,800.00 CHF |
| 2025-04-17 | N/A | Executive member | Sell | None | 13,344.49 CHF |
| 2025-03-18 | N/A | Non-Executive member | Buy | None | 38,200.00 CHF |
| 2024-12-11 | N/A | Executive member | Sell | None | 4,702,500.00 CHF |
| 2024-11-15 | N/A | Non-Executive member | Buy | None | 925,210.00 CHF |
| 2024-11-14 | N/A | Non-Executive member | Sell | None | 592,000.00 CHF |
| 2024-11-12 | N/A | Executive member | Sell | None | 13,890.86 CHF |
| 2024-09-25 | N/A | Executive member | Sell | None | 8,226,000.00 CHF |
| 2024-09-25 | N/A | Non-Executive member | Sell | None | 3,656,000.00 CHF |
| 2024-09-24 | N/A | Non-Executive member | Buy | None | 223,720.00 CHF |
Peer Companies
